Histamine‐2(H2 ) Antagonists can be safely removed from standard Paclitaxel Pre‐medication regimens

BOPA

Journal Article

Adverse Reactions

Paclitaxel

H2-Antagonists

Authors

Emma Foreman

Calum Polwart

Andrew Walker

Pinkie Chambers

Published

April 25, 2022

Keywords

Oncology, Pharmacy, Data, Real-World Outcomes, Software, Open Source

Following the BOPA poster presented at the BOPA 2021 Symposium, Andrew Walker joined us to provide a more detailed narrative of the background of H2 antagonists in taxane pre-medication. Andrew had previously undertaken an extensive literature review of the topic.

This paper was then published in the British Journal of Clinical Pharmacology.

— Content on this website has been produced with reasonable care. However, errors can occur. Opinions change over time. Code that worked at the time of publication may no longer work. Users of all content from this site do so at their own risk.

Reuse

CC BY-NC-ND 4.0

Copyright

Citation

BibTeX citation:

@article{foreman2022,
  author = {Foreman, Emma and Polwart, Calum and Walker, Andrew and
    Chambers, Pinkie},
  title = {Histamine‐2(H2 ) {Antagonists} Can Be Safely Removed from
    Standard {Paclitaxel} {Pre‐medication} Regimens},
  journal = {British Journal of Clinical Pharmacology},
  volume = {88},
  number = {9},
  date = {2022-04-25},
  url = {https://doi.org/10.1111/bcp.15363},
  doi = {10.1111/bcp.15363},
  langid = {en}
}

For attribution, please cite this work as:

1. Foreman, E., Polwart, C., Walker, A., & Chambers, P. (2022). Histamine‐2(H2 ) Antagonists can be safely removed from standard Paclitaxel Pre‐medication regimens. British Journal of Clinical Pharmacology, 88(9). https://doi.org/10.1111/bcp.15363